Table 3. Most common a any-grade treatment-related adverse events (TRAEs) in all patients with metastatic renal cell carcinoma according to interval analysis.
| Any-grade TRAE | Patients, n (%) | ||||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| 0–<6 mo (N = 5739) |
0–<1 yr (N = 5739) |
1–<2 yr (N = 1982) |
2–<3 yr (N = 807) |
3–<4 yr (N = 365) |
4–<5 yr (N = 168) |
5–<6 yr (N = 77) |
|
| Any | 5449 (95) | 5472 (95) | 1905 (96) | 767 (95) | 340 (93) | 157 (93) | 72 (94) |
| Diarrhea | 2342 (41) | 2692 (47) | 942 (48) | 378 (47) | 153 (42) | 65 (39) | 29 (38) |
| Fatigue | 2193 (38) | 2383 (42) | 796 (40) | 317 (39) | 130 (36) | 56 (33) | 25 (32) |
| Nausea | 1905 (33) | 2101 (37) | 438 (22) | 147 (18) | 53 (15) | 26 (15) | 10 (13) |
| Decreased appetite | 1566 (27) | 1770 (31) | 400 (20) | 113 (14) | 34 (9) | 17 (10) | 7 (9) |
| Dysgeusia | 1504 (26) | 1579 (28) | 411 (21) | 113 (14) | 40 (11) | 15 (9) | 8 (10) |
| Stomatitis | 1486 (26) | 1585 (28) | 313 (16) | 86 (11) | 25 (7) | 17 (10) | 12 (16) |
| Mucosal inflammation | 1455 (25) | 1566 (27) | 355 (18) | 100 (12) | 40 (11) | 22 (13) | 8 (10) |
| Vomiting | 1307 (23) | 1494 (26) | 256 (13) | 72 (9) | 20 (5) | 14 (8) | 3 (4) |
| Hypertension | 1195 (21) | 1349 (24) | 464 (23) | 204 (25) | 94 (26) | 46 (27) | 23 (30) |
| Hand–foot syndrome | 1228 (21) | 1487 (26) | 664 (34) | 251 (31) | 106 (29) | 52 (31) | 22 (29) |
| Thrombocytopenia | 1072 (19) | 1184 (21) | 226 (11) | 47 (6) | 18 (5) | 3 (2) | 1 (1) |
| Asthenia | 1011 (18) | 1130 (20) | 316 (16) | 76 (9) | 30 (8) | 11 (7) | 5 (6) |
| Dyspepsia | 989 (17) | 1109 (19) | 362 (18) | 136 (17) | 59 (16) | 27 (16) | 16 (21) |
| Rash | 850 (15) | 982 (17) | 246 (12) | 77 (10) | 22 (6) | 15 (9) | 5 (6) |
| Neutropenia | 705 (12) | 816 (14) | 309 (16) | 70 (9) | 37 (10) | 12 (7) | 4 (5) |
| Anemia | 643 (11) | 797 (14) | 317 (16) | 102 (13) | 36 (10) | 15 (9) | 8 (10) |
| Hair color changes | 578 (10) | 657 (11) | 322 (16) | 135 (17) | 62 (17) | 29 (17) | 11 (14) |
| Hypothyroidism | 166 (3) | 392 (7) | 482 (24) | 241 (30) | 118 (32) | 55 (33) | 32 (42) |
a
Occurring in at least 15% of patients in any one interval.